ADC Therapeutics

Business predictability is low. Revenue depends on a single product under accelerated or conditional approvals in key markets. The LOTIS‑5 dataset met PFS but showed higher SAEs and deaths in the test arm, leaving an uncertain regulatory and commercial path. TTM free cash flow is negative and quarterly wholesaler ordering patterns add noise.

Macro headwinds from competing modalities and potential label adjustments can shift trajectories quickly.